(MENAFN- PR Newswire)
RADNOR, Pa., June 7, 2022 /PRNewswire/ — NRx Prescribed drugs, Inc. (Nasdaq: NRXP ), a clinical-stage biopharmaceutical enterprise, announced these days that the company’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Main Economical Officer and Treasurer successful June 13, 2022.
Seth Van Voorhees
‘Dr. Van Voorhees is a highly accomplished CFO with intensive experience in company finance, cash marketplaces, investment banking and licensing. His appointment comes at an crucial time for our Organization, as we are focusing our resources principally on our psychiatry franchise. His monetary and scientific knowledge will be instrumental in encouraging us to continue to expand the Company,’ claimed Robert Besthof, Interim Main Government Officer of NRx Pharmaceuticals. ‘We are grateful to Ira Strassberg for his significant contributions to the Corporation since last August, including the establishment of robust interior controls and the further more establish-up of our finance and accounting perform at the Firm.’
‘I am delighted to be a part of NRx Prescribed drugs at this remarkable stage, as the Company is concentrating principally on the enhancement of NRX-101, its Breakthrough Designation Therapy for Extreme Bipolar Melancholy in people with Acute Suicidal Ideation and Actions (ASIB). Its scientific platform generates eye-catching prospects to handle the pretty substantial unmet have to have of dealing with bipolar melancholy in individuals with suicidality, as very well as other psychiatric disorders. Up to 50% of individuals with bipolar ailment try suicide in excess of their life span, and patients with bipolar depression and suicidality have historically been excluded from medical research. The Firm is previously enrolling patients in a Period II trial researching patients with bipolar depression and sub-acute suicidality (not requiring hospitalization) and options to initiate a Stage IIb/III registrational demo in people with bipolar melancholy and ASIB (necessitating hospitalization) later on this calendar year,’ explained Dr. Van Voorhees.
Dr. Van Voorhees most lately served as CFO of PDS Biotechnology all through which he done a number of funding transactions in 2021. Prior to signing up for PDS Biotechnology, he put in 10 decades as the CFO for Exploration Frontiers and for American Pacific. Earlier in his career, Dr. Van Voorhees labored in investment decision banking supporting chemical/pharmaceutical customers at Merrill Lynch, UBS Warburg, and Wasserstein Perella. He gained a Ph.D. in chemistry from the University of Pennsylvania and an MBA from Columbia College.
About NRx Pharmaceuticals
NRx Prescribed drugs, Inc. (‘NRx Pharmaceuticals’ or the ‘Company’) attracts upon many years of collective, scientific, and drug-enhancement knowledge to deal with pretty significant unmet needs of individuals and provide enhanced health and fitness to patients. The U.S. Meals and Drug Administration (‘FDA’) has additionally granted Breakthrough Remedy designation, a Specific Protocol Agreement, and a Biomarker Letter of Help for NRX-101, an investigational medication for the procedure of serious bipolar melancholy in patients with acute suicidal ideation and habits (ASIB) right after original stabilization with ketamine or other powerful therapy. NRx Prescribed drugs is led by executives who have held management roles at Lilly, Pfizer, and Novartis as perfectly as major financial investment banking establishments.
Cautionary Be aware Relating to Ahead-Seeking Statements
This announcement of NRx Prescription drugs, Inc. consists of ‘forward-seeking statements’ in just the which means of the ‘safe harbor’ provisions of the U.S. Personal Securities Litigation Reform Act of 1995, which might incorporate, but are not limited to, statements concerning our monetary outlook, merchandise progress, company potential customers, and industry and sector developments and disorders, as well as the Firm’s strategies, options, goals, and plans. These ahead-seeking statements are based mostly on present-day beliefs, anticipations, estimates, forecasts, and projections of, as properly as assumptions built by, and details at this time offered to, the Company’s management.
The Enterprise assumes no obligation to revise any forward-seeking assertion, no matter if as a outcome of new information and facts, long run activities or in any other case. Accordingly, you should not place reliance on any forward-looking assertion, and all forward-looking statements are herein qualified by reference to the cautionary statements established forth higher than.
Company Call Molly CoganSr. Director, World wide Communications [email protected]
Investor RELATIONS Tim McCarthyInvestor Relations[email protected]
Source NRx Prescribed drugs, Inc.
Authorized Disclaimer: MENAFN presents the data “as is” with out guarantee of any form. We do not take any responsibility or liability for the accuracy, information, photographs, videos, licenses, completeness, legality, or reliability of the info contained in this write-up. If you have any issues or copyright challenges similar to this write-up, kindly call the supplier over.